A citation-based method for searching scientific literature

William J Gradishar, Meena S Moran, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H Allison, Bethany Anderson, Harold J Burstein, Helen Chew, Chau Dang, Anthony D Elias, Sharon H Giordano, Matthew P Goetz, Lori J Goldstein, Sara A Hurvitz, Steven J Isakoff, Rachel C Jankowitz, Sara H Javid, Jairam Krishnamurthy, Marilyn Leitch, Janice Lyons, Joanne Mortimer, Sameer A Patel, Lori J Pierce, Laura H Rosenberger, Hope S Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M Stringer-Reasor, Melinda L Telli, John H Ward, Kari B Wisinski, Jessica S Young, Jennifer Burns, Rashmi Kumar. J Natl Compr Canc Netw 2022
Times Cited: 39







List of co-cited articles
86 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
17

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
A Gennari, F André, C H Barrios, J Cortés, E de Azambuja, A DeMichele, R Dent, D Fenlon, J Gligorov, S A Hurvitz,[...]. Ann Oncol 2021
116
12

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, Brittany E Harvey, Pamela B Mangu, John M S Bartlett, Michael Bilous, Ian O Ellis, Patrick Fitzgibbons, Wedad Hanna,[...]. J Clin Oncol 2018
759
12

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
H J Burstein, G Curigliano, B Thürlimann, W P Weber, P Poortmans, M M Regan, H J Senn, E P Winer, M Gnant. Ann Oncol 2021
110
10

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Fabrice Andre, Nofisat Ismaila, Kimberly H Allison, William E Barlow, Deborah E Collyar, Senthil Damodaran, N Lynn Henry, Komal Jhaveri, Kevin Kalinsky, Nicole M Kuderer,[...]. J Clin Oncol 2022
28
14


Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Laslo Roman, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Staroslawska, Juan de la Haba-Rodriguez, Seock-Ah Im,[...]. Lancet Oncol 2012
7

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Maggie C U Cheang, Stephen K Chia, David Voduc, Dongxia Gao, Samuel Leung, Jacqueline Snider, Mark Watson, Sherri Davies, Philip S Bernard, Joel S Parker,[...]. J Natl Cancer Inst 2009
7

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.
F Cardoso, S Kyriakides, S Ohno, F Penault-Llorca, P Poortmans, I T Rubio, S Zackrisson, E Senkus. Ann Oncol 2019
644
7

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, Della F Makower, Kathleen I Pritchard, Kathy S Albain, Daniel F Hayes, Charles E Geyer, Elizabeth C Dees, Matthew P Goetz, John A Olson,[...]. N Engl J Med 2018
7

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
Torsten O Nielsen, Samuel C Y Leung, David L Rimm, Andrew Dodson, Balazs Acs, Sunil Badve, Carsten Denkert, Matthew J Ellis, Susan Fineberg, Margaret Flowers,[...]. J Natl Cancer Inst 2021
133
7

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, Shannon E McKernin, Lisa A Carey, Patrick L Fitzgibbons, Daniel F Hayes, Sunil R Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter,[...]. J Clin Oncol 2020
320
7

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Mila Donker, Geertjan van Tienhoven, Marieke E Straver, Philip Meijnen, Cornelis J H van de Velde, Robert E Mansel, Luigi Cataliotti, A Helen Westenberg, Jean H G Klinkenbijl, Lorenzo Orzalesi,[...]. Lancet Oncol 2014
915
7

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa,[...]. Lancet 2014
7

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
7

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019.
H J Burstein, G Curigliano, S Loibl, P Dubsky, M Gnant, P Poortmans, M Colleoni, C Denkert, M Piccart-Gebhart, M Regan,[...]. Ann Oncol 2019
317
7

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
7

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Maria Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T Ueno, Aleix Prat, Yee Soo Chae,[...]. N Engl J Med 2022
114
7

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, Brittany E Harvey, Pamela B Mangu, John M S Bartlett, Michael Bilous, Ian O Ellis, Patrick Fitzgibbons, Wedad Hanna,[...]. Arch Pathol Lab Med 2018
354
7



A careful reassessment of anthracycline use in curable breast cancer.
Sara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, Michael F Press, Mark Pegram, John P Crown, Peter A Fasching, Bent Ejlertsen, Eric H Yang, John A Glaspy,[...]. NPJ Breast Cancer 2021
15
13

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Luca Gianni, Tadeusz Pienkowski, Young-Hyuck Im, Ling-Ming Tseng, Mei-Ching Liu, Ana Lluch, Elżbieta Starosławska, Juan de la Haba-Rodriguez, Seock-Ah Im, Jose Luiz Pedrini,[...]. Lancet Oncol 2016
428
5

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019
988
5

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Luca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, Alexey Manikhas, Ana Lluch, Sergey Tjulandin, Milvia Zambetti, Federico Vazquez, Mikhail Byakhow, Mikhail Lichinitser,[...]. Lancet 2010
814
5

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Vincent O Dezentjé, Irma M Oving, Aafke H Honkoop, Lidwine W Tick, Agnes J van de Wouw,[...]. Lancet Oncol 2018
126
5

Breast cancer: from "maximum tolerable" to "minimum effective" treatment.
Umberto Veronesi, Vaia Stafyla, Alberto Luini, Paolo Veronesi. Front Oncol 2012
30
6

Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Nasim Mavaddat, Daniel Barrowdale, Irene L Andrulis, Susan M Domchek, Diana Eccles, Heli Nevanlinna, Susan J Ramus, Amanda Spurdle, Mark Robson, Mark Sherman,[...]. Cancer Epidemiol Biomarkers Prev 2012
377
5

Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.
Bernard Fisher, Stewart Anderson, John Bryant, Richard G Margolese, Melvin Deutsch, Edwin R Fisher, Jong-Hyeon Jeong, Norman Wolmark. N Engl J Med 2002
5

Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Linda S Lindström, Christina Yau, Kamila Czene, Carlie K Thompson, Katherine A Hoadley, Laura J Van't Veer, Ron Balassanian, John W Bishop, Philip M Carpenter, Yunn-Yi Chen,[...]. J Natl Cancer Inst 2018
35
5


The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18F-Fluoroestradiol PET/CT.
Zhongyi Yang, Yifei Sun, Xiaoping Xu, Yongping Zhang, Jianping Zhang, Jing Xue, Mingwei Wang, Huiyu Yuan, Silong Hu, Wei Shi,[...]. Clin Nucl Med 2017
28
7

Ki67 in breast cancer: prognostic and predictive potential.
Rinat Yerushalmi, Ryan Woods, Peter M Ravdin, Malcolm M Hayes, Karen A Gelmon. Lancet Oncol 2010
742
5

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, Gong Tang, Chungyeul Kim, Joffre Baker, Maureen Cronin, Frederick L Baehner, Michael G Walker, Drew Watson, Taesung Park,[...]. N Engl J Med 2004
5


Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
N Harbeck, P Rastogi, M Martin, S M Tolaney, Z M Shao, P A Fasching, C S Huang, G G Jaliffe, A Tryakin, M P Goetz,[...]. Ann Oncol 2021
88
5

Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer.
Armando E Giuliano, Stephen B Edge, Gabriel N Hortobagyi. Ann Surg Oncol 2018
229
5

Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.
Sun Young Chae, Sei Hyun Ahn, Sung-Bae Kim, Sangwon Han, Suk Hyun Lee, Seung Jun Oh, Sang Ju Lee, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee,[...]. Lancet Oncol 2019
42
5

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
Harold J Burstein, Mark R Somerfield, Debra L Barton, Ali Dorris, Lesley J Fallowfield, Dharamvir Jain, Stephen R D Johnston, Larissa A Korde, Jennifer K Litton, Erin R Macrae,[...]. J Clin Oncol 2021
32
6

NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021.
Efrat Dotan, Louise C Walter, Ilene S Browner, Katherine Clifton, Harvey Jay Cohen, Martine Extermann, Cary Gross, Sumati Gupta, Genevieve Hollis, Joleen Hubbard,[...]. J Natl Compr Canc Netw 2021
31
6

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
5

The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
Mahul B Amin, Frederick L Greene, Stephen B Edge, Carolyn C Compton, Jeffrey E Gershenwald, Robert K Brookland, Laura Meyer, Donna M Gress, David R Byrd, David P Winchester. CA Cancer J Clin 2017
5

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
Harry D Bear, Stewart Anderson, Roy E Smith, Charles E Geyer, Eleftherios P Mamounas, Bernard Fisher, Ann M Brown, Andre Robidoux, Richard Margolese, Morton S Kahlenberg,[...]. J Clin Oncol 2006
670
5

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
803
5

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J A van der Hage, C J van de Velde, J P Julien, M Tubiana-Hulin, C Vandervelden, L Duchateau. J Clin Oncol 2001
750
5

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Gunter von Minckwitz, Michael Untch, Jens-Uwe Blohmer, Serban D Costa, Holger Eidtmann, Peter A Fasching, Bernd Gerber, Wolfgang Eiermann, Jörn Hilfrich, Jens Huober,[...]. J Clin Oncol 2012
5


The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Lisa A Carey, E Claire Dees, Lynda Sawyer, Lisa Gatti, Dominic T Moore, Frances Collichio, David W Ollila, Carolyn I Sartor, Mark L Graham, Charles M Perou. Clin Cancer Res 2007
5

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
Priya Rastogi, Stewart J Anderson, Harry D Bear, Charles E Geyer, Morton S Kahlenberg, André Robidoux, Richard G Margolese, James L Hoehn, Victor G Vogel, Shaker R Dakhil,[...]. J Clin Oncol 2008
5

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D J Slamon, W Godolphin, L A Jones, J A Holt, S G Wong, D E Keith, W J Levin, S G Stuart, J Udove, A Ullrich. Science 1989
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.